1,721,060 research outputs found
Weight-based dosing: which impact on efficacy and safety of therapy?
No full textPegylated interferons (PEG-IFNs) in combination with ribavirin represent the most recent advance in the treatment of patients withchronic hepatitis C (CHC): two large clinical trials have shown a superior efficacy in clearing HCV in almost 60% of treated naïve patients. Responses to antiviral treatment of CHC vary according to both viral and host factors. Managing patients with CHC infection requires individualised treatment strategies to optimise outcomes. Several landmark publications on PEG-IFNs have reported that weight is a significant predictive factor for SVR in the treatment of CHC with fixed-dose drug administration. With fixed-dose treatment, there is a direct correlation between increasing body weight and decreasing rate of SVR. As patient's weight increases, fixed-dose therapy provides proportionately lower amounts of drug. Therefore, under this dosing scheme, heavier patients do not have an equal chance at achieving SVR as do lighter patients. Unfortunately though, lighter patients may also suffer, as fixed dosing can provide these patients with an excessive amount of drug, increasing their risk for adverse events. Individualised weight-adjusted dosing of both PEG-IFN and ribavirin might represents the best treatment strategy to assure that all patients have the same opportunity to achieve SVR
Studio dei meccanismi molecolari di risposta al sorafenib e identificazione di nuovi bersagli terapeutici per il trattamento del carcinoma epatocellulare
Full text linkESPRESSIONE DI VEGF, HSP90 E Bip/GRP78 E RICORRENZA DI CARCINOMA EPATOCELLULARE DOPO TRAPIANTO DI FEGATO
Full text linkBackground and aims
Liver transplantation (LT) for hepatocellular carcinoma (HCC) is a satisfactory therapeutic choice in patients with “early HCC” selected according to Milan criteria. However, the risk of HCC recurrence after LT is about 7-10% at five years and markers which can predict recurrence are still lacking. We investigated in HCC samples and LC surrounding tissues the significance of VEGF, HSP90, and Bip/GRP78 expression in patients with HCC who underwent LT in a western transplantation center and their possible role as markers of recurrence.Background and aims
Liver transplantation (LT) for hepatocellular carcinoma (HCC) is a satisfactory therapeutic choice in patients with “early HCC” selected according to Milan criteria. However, the risk of HCC recurrence after LT is about 7-10% at five years and markers which can predict recurrence are still lacking. We investigated in HCC samples and LC surrounding tissues the significance of VEGF, HSP90, and Bip/GRP78 expression in patients with HCC who underwent LT in a western transplantation center and their possible role as markers of recurrence
POLIMORFISMI A SINGOLO NUCLEOTIDE ( SINGLE NUCLEOTIDE POLYMORPHISMS, SNPs) COME POSSIBILI MARCATORI GENETICI PER LA VALUTAZIONE DEL RISCHIO DI SVILUPPO DI EPATOCARCINOMA IN PAZIENTI CON CIRROSI EPATICA HCV-CORRELATA
Full text linkRUOLO DELL'INTERAZIONE KIRs/HLA NEI PAZIENTI CON INFEZIONE CRONICA DA HBV
Full text linkBackground:
The Natural Killer (NK) cells provide a major defense against several infections and their activity is regulated partially through inhibitory and activating killer cell immunoglobulin - like receptors (KIRs) interacting with human leukocyte antigens (HLA) class I molecules. The aim of this study is to assess whether the KIR and HLA repertoire may influence the course of hepatitis B virus (HBV) infection.
Methods:
Till now, twenty – four patients with chronic HBV infection have been genotyped for KIRs and their HLA ligands, along with non-exposed subjects (HBsAg negative, anti - HBcAb positive with or without anti - HBsAb) as controls.
Results:
All the KIR haplotypes are represented in the same way. The frequency of KIR2DS2 is higher in patients with chronic HBV infection than in non-exposed subjects (75 % vs 45 % respectively, OR 3.7, p= 0.02) but its interaction with the cognate ligand HLA C1 is not significantly different in the two groups (42% vs 22% respectively, OR 2,58, p= n.s.) .
HLA C2 (87% vs 60% respectively, OR 4.67, p= 0.03), HLA Bw4I (58% vs 37% respectively, OR 3.45, p= 0.03) and HLA A 3, 11 (71% vs 10%, OR 21.86, p= < 0.00001) are more frequent in patients with chronic HBV infection than in non-exposed subjects so as the inhibitory KIR3DL2 - HLA A 3,11 (71 % vs 10 % respectively, p < 0,00001, OR 21,86) and KIR2DL2-HLA C1 (58% vs 28% respectively, p= 0.02, OR 3.54) interactions.
Conclusions:
Our results are consistent with others reported in the recent literature. To sum up, the frequency of inhibitory interactions is higher in patients with chronic HBV infection than in non exposed subjects and the two groups are genetically different. The HLA A 3,11 is strongly represented in the patients group and this result has never been reported in the literature
VALUTAZIONE RM E TC DELLA RISPOSTA AL TRATTAMENTO CON SORAFENIB IN PAZIENTI CIRROTICI CON EPATOCARCINOMA
Full text link
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
- …
